[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin,2016,66:115-132.
[2] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版).临床肿瘤学杂志,2011,16:929-946.
[3] Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology,2011,10:761-780.
[4] Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the nonin-vasive diagnostic criteria for hepatocellular carcinoma. Hepatology,2008,47:2146-2147.
[5] 徐娟,赵晔,李俊芝.原发性肝癌超声造影诊断的特征性声像图表现.肝脏,2016,21:441-443.
[6] Yoshida K, Hirokawa T, Moriyasu F,et al. Arterial-phase contrastenhanced ultrasonography for evaluating anti-angiogenesis treatment: a pilot study. World J Gastroenterol,2011,17:1045-1050.
[7] 宋彬,吴菇.肝细胞癌的影像学研究现状与进展西部医学.西部医学,2015,27:481-485.
[8] Song DS, Si HB. Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period. Clin Mol Hepatol,2012,18:258-267.
[9] 王光宪,文利.肝癌的影像学诊断进展.实用放射学杂志,2014,30:1043-1045.
[10] Kysucan J, Lovecek M, Klos D, et al. Benefit of PET/CT in the preoperative staging in pancreatic carcinoma.Rozhledy,2010,89:433-440.
[11] Min JK, Choi JI, Lee JS, et al. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma. J Gastroen Hepatol,2011,26:1201-1206.
[12] Jiang T, Kambadakone A, Kulkarni NM, et al. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol,2012,47:11-17.
[13] Yang L, Zhang XM, Zhou XP, et al. Correlation between tumor perfusion and lipiodol deposition in hepatocellular carcinoma after transarterial chemoembolization. J Vasc Interv Radiol,2010,21:1841-1846.
[14] 林晓珠,沈云,陈克敏.CT能谱成像的基本原理与临床应用研究进展.中华放射学杂志,2011,45:798-800.
[15] Apfaltrer P, Meyer M, Meier C, et al. Contrast-enhanced dual-energy CT of gastrointestinal stromal tumors: is iodine-related attenuation a potential indicator of tumor response Invest Radiol,2012,47:65-70.
[16] Kelekis NL, Semelka RC, Worawattanakul S, et al. Hepatocellular carcinoma in North Am Erica: a m ultiinstitutional study of appearance on T1-weighted,T2-weighted,and serial gadolinium-enhanced gradient- echo images. AJR,1998,170:1005-1013.
[17] 徐宇崇,刘荣华,赵志刚,等.原发性肝细胞性肝癌CT 动态增强不典型表现分析.临床医药实践,2012,21:791-792.
[18] Ishigami K, Yoshimitsu K, Nishihara Y, et al. Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology,2009,250: 435-443.
[19] Surachate S, Lee JK, Raman SS, et al. MRI Detection of Intratumoral Fat in Hepatocellular Carcinoma: Potential Biomarker for a More Favorable Prognosis. AJR,2012,199:1018-1025.
[20] 岳倩倩,王新怡. 肝细胞肝癌分子靶向治疗的影像学评价进展.中华临床医师杂志(电子版),2016,10:112-116.
[21] Xu P, Zeng M, Liu K, et al. Microvaseular invasion in small Hepatocellular carcinoma: Is it predictable with preoperative diffusion-weighted imaging. J Gastroen Hepatol,2014,29: 330-336.
[22] Babsky AM, Ju S, George B, et al. Predicting response to benzamide riboside chemotherapy in hepatocellular carcinoma using apparent diffusion coefficient of water. Anticancer Research,2011,1:2045-2051.
[23] 杨蓓,王翔,金朝林.MRI弥散加权成像在肝硬化患者直径＜2cm肝癌早期诊断中的应用.肝脏,2015,3:183-185.
[24] Nakanishi M, Chuma M, Hige S, et al. Relationship between diffusion-weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma. Annals of Surgical Oncology,2012,19:318-321.
[25] Dudeck O, Zeile M, Wybranski C, et al. Early prediction of anticancer effects with diffusion-weighted MR imaging in patients with colorectal liver metastases following selective internal radiotherapy. European Radiology,2010,20:2699-2706.
[26] 魏君臣,李献祖,胡喜斌,等.肝脏磁共振扩散加权成像对肝癌化疗栓塞后疗效评价的实验性研究.临床放射学杂志,2012,31:578-581.
[27] Vilgrain V. Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments: hepatocellular carcinoma: imaging in assessing treatment efficacy. JHBPS,2010,17:374-379.
[28] Lee JM, Choi BI. Hepatocellular nodules in liver cirrhosis:MR evaluation. Abdom Imaging,2011,36:282-289.
[29] Kuo YT, Li CW, Chen CY, et al. In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. JMRI,2004,19:598-604.
[30] Reeder SB, Cruite I, Hamilton G, et a. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. JMRI,2011,34:729-749.
[31] Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology,2011,10:761-780.
[32] 罗琳,单鸿,王劲.钆塞酸二钠在肝硬化性结节及小肝癌评估中的应用进展.中华肝胆外科杂志,2013,19:955-960.
[33] Yoo HJ, Lee JM, Lee JY, et al. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatoceltular carcinoma in cirrhotic liver. Invest Radiol,2009,44:800-807.
[34] Sano K, Ichikawa T, Motosugi U, et al. Imaging study of early hepatocellular carcinoma:usefulness of gadoxetic-acidenhanced MR imaging. International Journal of Medical Radiology,2012,261:834-844.
[35] Ishimaru H, Nakashima K, Sakugawa T, et al. Local recurrence after chemoembolization of hepatcellu1ar carcinoma: uptake of gadoxetic acid as a new prognostic factor. AJR,2014,202:744-751.
[36] Choi JW, Lee JM, Kim SJ, et al. Hepatocellular carcinoma:imaging patterns on gadoxetic acid-enhanced M R Images and their value as an imaging biomarker. Radiology,2013,267:776-786. |
